The Translational Respiratory Immunology Lab (TRIL) aims to design novel treatments for chronic and acute respiratory conditions. By harnessing the unique properties of gut microbial-derived compounds and their metabolites we aim to modulate the lungs' immune system and improve our protection against infections and inflammatory diseases of the airways. Our research programme is focused on a coherent and integrative approach at the intersection of basic and clinical research to enable innovative, simple and cost-effective therapies for respiratory care.